In-vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides.
The in-vitro activity of pefloxacin was evaluated against 360 Enterobacteriaceae, 143 Pseudomonas aeruginosa and 124 staphylococci, selected for multiply resistance to different beta-lactam antibiotics and aminoglycosides. The MIC90 of pefloxacin against staphylococci and most Enterobacteriaceae was 0.5 mg/l or less. The MIC90 against Serratia marcescens and P. aeruginosa varied between 4 and 8 mg/l. Time-killing curves showed that pefloxacin at concentrations of four times the MIC decreased the viable counts by 3 logs or more within 1-8 h.
D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D009643:Norfloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D015366:Pefloxacin; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D047090:beta-Lactams
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D015366:Pefloxacin; D009643:Norfloxacin